EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:229233 - ritlecitinib
| Formula | C15H19N5O |
| Net Charge | 0 |
| Average Mass | 285.351 |
| Monoisotopic Mass | 285.15896 |
| SMILES | C=CC(=O)N1C[C@H](Nc2ncnc3nccc23)CC[C@@H]1C |
| InChI | InChI=1S/C15H19N5O/c1-3-13(21)20-8-11(5-4-10(20)2)19-15-12-6-7-16-14(12)17-9-18-15/h3,6-7,9-11H,1,4-5,8H2,2H3,(H2,16,17,18,19)/t10-,11+/m0/s1 |
| InChIKey | CBRJPFGIXUFMTM-WDEREUQCSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Chemical Role: | Bronsted base A molecular entity capable of accepting a hydron from a donor (Brønsted acid). |
| Biological Roles: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that specifically blocks the action of non-specific protein-tyrosine kinase (EC 2.7.10.2). |
| Applications: | immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antirheumatic drug A drug used to treat rheumatoid arthritis. anti-inflammatory drug A substance that reduces or suppresses inflammation. dermatologic drug A drug used to treat or prevent skin disorders or for the routine care of skin. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| ritlecitinib (CHEBI:229233) has role anti-inflammatory drug (CHEBI:35472) |
| ritlecitinib (CHEBI:229233) has role antirheumatic drug (CHEBI:35842) |
| ritlecitinib (CHEBI:229233) has role dermatologic drug (CHEBI:50177) |
| ritlecitinib (CHEBI:229233) has role EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor (CHEBI:76617) |
| ritlecitinib (CHEBI:229233) has role immunosuppressive agent (CHEBI:35705) |
| ritlecitinib (CHEBI:229233) is a N-acylpiperidine (CHEBI:48591) |
| ritlecitinib (CHEBI:229233) is a acrylamides (CHEBI:22216) |
| ritlecitinib (CHEBI:229233) is a pyrrolopyrimidine (CHEBI:38670) |
| ritlecitinib (CHEBI:229233) is a secondary amino compound (CHEBI:50995) |
| ritlecitinib (CHEBI:229233) is a tertiary carboxamide (CHEBI:140326) |
| ritlecitinib (CHEBI:229233) is conjugate base of ritlecitinib(1+) (CHEBI:229235) |
| Incoming Relation(s) |
| ritlecitinib(1+) (CHEBI:229235) is conjugate acid of ritlecitinib (CHEBI:229233) |
| IUPAC Name |
|---|
| 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one |
| INNs | Source |
|---|---|
| ritlecitinib | WHO MedNet |
| ritlecitinib | WHO MedNet |
| ritlécitinib | WHO MedNet |
| ritlecitinibum | WHO MedNet |
| Synonyms | Source |
|---|---|
| PF 06651600 | ChEBI |
| PF-06651600 | DrugBank |
| PF06651600 | ChEBI |
| Manual Xrefs | Databases |
|---|---|
| DB14924 | DrugBank |
| Ritlecitinib | Wikipedia |
| Registry Numbers | Sources |
|---|---|
| CAS:1792180-81-4 | DrugBank |
| Citations |
|---|